We are live on ! Find out more
CP

Covenant Partners Portfolio holdings

AUM $342M
1-Year Est. Return 19.24%
This Fund
S&P 500
This Quarter Est. Return
+6.32%
1 Year Est. Return
+19.24%
3 Year Est. Return
+70.32%
5 Year Est. Return
+79.29%
10 Year Est. Return
AUM
$265M
AUM Growth
+$13.8M
Cap. Flow
-$371K
Cap. Flow %
-0.14%
Top 10 Hldgs %
49.35%
Holding
208
New
7
Increased
11
Reduced
28
Closed
7

Sector Composition

Rank Sector Weight
1 Technology 17.39%
2 Healthcare 8.06%
3 Financials 7.83%
4 Consumer Discretionary 6.21%
5 Industrials 6.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IWM icon
201
iShares Russell 2000 ETF
IWM
$80.9B
$20K 0.01%
89
BMRN icon
202
BioMarin Pharmaceuticals
BMRN
$11.5B
-3,054
Closed -$231K
BWA icon
203
BorgWarner
BWA
$13.2B
-5,227
Closed -$213K
NBIX icon
204
Neurocrine Biosciences
NBIX
$17.7B
-2,055
Closed -$200K
RGA icon
205
Reinsurance Group of America
RGA
$15.7B
-1,674
Closed -$211K
SAIA icon
206
Saia
SAIA
$11.3B
-876
Closed -$202K
SUI icon
207
Sun Communities
SUI
$15B
-1,526
Closed -$229K
WEC icon
208
WEC Energy
WEC
$37.7B
-2,389
Closed -$224K

Similar funds

Covenant Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Covenant Partners held 208 positions worth $265M, up 5.5% from $251M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Covenant Partners's Q2 2021 filing shows 7 new, 11 increased, 28 reduced and 7 closed positions. Its largest new stake was Unilever: 5,724 shares worth $377K. The largest sale was Takeda Pharmaceutical, an estimated $487K.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.

  • Covenant Partners's largest Q2 2021 buy was Unilever: 5,724 shares worth $377K.
  • Covenant Partners added most to iShares MSCI EAFE Value ETF in Q2 2021, an estimated $930K increase.
  • Covenant Partners's biggest Q2 2021 reduction was Takeda Pharmaceutical, cutting an estimated $487K.
  • Covenant Partners fully exited BioMarin Pharmaceuticals in Q2 2021, selling an estimated $231K.
  • Covenant Partners's ten largest holdings make up 49% of its $265M portfolio in Q2 2021.
  • Covenant Partners opened 7 new positions and closed 7 in Q2 2021.
  • Covenant Partners's portfolio value rose 5.5% quarter-over-quarter to $265M.

Based on Covenant Partners's 13F filing for Q2 2021, filed 2 Aug 2021.